We have been through this issue a couple of times. Simply being on a retail shelf will generate minimal sales unless it is coupled with an advertising/education campaign. Remember, 99.9% of the US population has no idea what ActiPatch, PEMF or SWT is and its advantages over drugs for pain relief.
Until this advertising/education campaign has funding, IMO, AW made the decision to keep sales flowing through the ActiPatch website where BIEL gets the full $29 rather than the wholesale price of $12-15 that having a retail shelf would net BIEL.
Deals like the CARE group that include customer education seem like the best vehicle right now until the resources for a campaign are available or that partnership is found.
Advertising/Education will create demand and then the retail shelf volume will more than make up for the lower wholesale profit margin. America has seen the carnage that pain killing drugs cause and is looking for new solutions.
Now that we have both FDA and NHS to use in promoting ActiPatch a very compelling campaign can be developed.
News 
Market Data 
Discover 
